Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Medical Oncology
•
Lymphoma
•
Internal Medicine
•
Hematology
Would you give CNS prophylaxis to a patient with Waldeyer's ring diffuse large B cell lymphoma if it is not triple or double hit ?
Risk of CNS relapse in a reported series is less than 5%.
Answer from: Medical Oncologist at Community Practice
Not if it's limited to this area only.
Sign in or Register to read more
7207
Related Questions
How would you manage a young patient with HL who develops HF (EF < 30%) after 4 cycles of A+AVD who obtained a PET2 CR?
How would you consolidate a patient with primary refractory double hit lymphoma with secondary CNS involvement?
Would you consider replacing ibrutinib with acalabrutinib or zanubrutinib in the TRIANGLE regimen for MCL in a patient with atrial fibrillation or high risk coronary syndromes who is otherwise fit for aggressive induction therapy?
How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?
How would you treat an elderly male with history of mantle cell lymphoma who relapsed after chemoimmunotherapy and cBTKi w/ multiple co-morbidities including CKD and CHF w/ low EF?
How would you treat a tDLBCL originally treated with R-CHOP who relapses with DLBCL 15 years after the original diagnosis?
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
How would you treat an older patient with B symptoms and biopsy consistent with grade 3 follicular lymphoma but noted to have a PET scan with SUV readings of > 20?
Have you utilized a dose-reduced approach for elderly patients receiving frontline Pola-R-CHP similar to R-miniCHOP?